Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012

CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released
A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer.

Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

New tool mines whole-exome sequencing data to match cancer with best drug
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.

Researchers identify potential targeted therapy for lung cancer using fly model
A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Improving access to clinical trials when biopsies are required
The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment.

Three hits to fight lung cancer
Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment.

Non-small cell lung cancers can be sorted in clusters by endocytic changes
In the Age of Personalized Medicine, we've learned that one size doesn't fit all, least of all in cancer. Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that cancer cell biologists are furiously pursuing.

Researchers identify biomarker of early lung cancer that may increase survival
Researchers in Taiwan have identified a biomarker that detects the most common lung cancer in its earliest stage. The discovery could one day change how long lung cancer patients live.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer
by National Comprehensive Cancer Network® (NCCN®) (Author)


[OFFICIAL CURRENT VERSION] From the medical leaders of 27 of the world’s most renowned cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to non-small cell lung cancer. Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about the diagnosis and treatment of lung cancer. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! Part 1 – Lung cancer basics: Explains how lung cancer starts and how it spreads Part 2 – Assessing lung nodules: Discusses care...

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

The MD Anderson Manual of Medical Oncology, Third Edition

The MD Anderson Manual of Medical Oncology, Third Edition
by Hagop M. Kantarjian (Author), Robert A. Wolff (Author)


Authoritative, hands-on desk reference for the practicing oncologist―from the leader in the field of cancer management and treatmentThe MD Anderson Manual of Medical Oncology details the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers pioneered by The University of Texas MD Anderson Cancer Center. Its pragmatic presentation can provide valuable insights at any stage of your career.This completely updated third edition reflects the most recent advancements, including expanded coverage of the rapidly evolving area of biological and immune therapies of cancer, many developed at MD Anderson. It emphasizes and discusses continuing developments in diagnostic procedures, which include the incorporation of new molecular markers and revised...

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO (nivolumab) is also indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO (nivolumab) treat your melanoma or lung cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)


The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and...

Being Mortal: Medicine and What Matters in the End

Being Mortal: Medicine and What Matters in the End
by Atul Gawande (Author)



In Being Mortal, bestselling author Atul Gawande tackles the hardest challenge of his profession: how medicine can not only improve life but also the process of its ending

Medicine has triumphed in modern times, transforming birth, injury, and infectious disease from harrowing to manageable. But in the inevitable condition of aging and death, the goals of medicine seem too frequently to run counter to the interest of the human spirit. Nursing homes, preoccupied with safety, pin patients into railed beds and wheelchairs. Hospitals isolate the dying, checking for vital signs long after the goals of cure have become moot. Doctors, committed to extending life, continue to carry out devastating procedures that in the end extend suffering.Gawande, a practicing surgeon, addresses his...

Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)
by Giuseppe Giaccone (Author)


Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens.

This pocketbook summarises the latest evidence-based and practical information on the...

Small Cell Lung Cancer - Treatment Options and Alternative Medicine

Small Cell Lung Cancer - Treatment Options and Alternative Medicine
by Christian Vazquez (Author)


Small Cell Lung Cancer is a full crash course on the topic. We reviewed over 300 of the strongest natural agents that exist for cancer and found only 6 that have conclusive evidence for small cell lung cancer. The biggest problem is not lack of information in the world, it is the lack of time, understanding of the medical data associated with scientific research and to top it off there is so much data in so many directions between the pharmaceutical, people trying to steer you in the wrong way to make a quick dollar, the quacks of the industry and everything else imaginable where at the end of the day the majority of information learned is wrong. Small cell lung cancer is the fastest growing cancer that exist, there is no time to research or postpone making a decision in treatment. It is...

© 2016 BrightSurf.com